Leading private equity firm NorthEdge has completed a multi-million-pound investment into Antibody Analytics, a contract research organisation (CRO) and trusted provider of immunology research services to an international client base, to support their continued growth.
Antibody Analytics is focused on supporting the developers of antibody-targeted therapeutics, complex biologics and immunotherapies, to help their clients get the best drug candidates into the clinic. The strategic investment will include significant job creation and expansion of its site, resulting in a world-class facility that will provide additional capacity and enable increased research capabilities, allowing the business to continue to develop pioneering solutions.
In line with Scotland’s ambitious Life Sciences strategy, this significant investment will also enable a multitude of job opportunities, not just within Antibody Analytics, but also in the broader Scottish Life Sciences sector, promising stability and growth for the region.
Andy Upsall, CEO of Antibody Analytics, said: “With this investment, we will continue to develop technologies and provide services that address the challenges the industry demands. Now more than ever, the developers of innovative biotherapeutics require specialist solutions, as they forge their way through the increasingly difficult and expensive drug development pathway. This is just the beginning of our journey to further impact patient outcomes and drive advancements in life sciences.”